Activity and electrochemical properties: iron complexes of the anticancer drug triapine and its analogs.

Antineoplastic Agents / chemistry Cell Line, Tumor Cell Proliferation / drug effects Coordination Complexes / chemistry Electrochemistry / methods Enzyme Inhibitors / chemistry Humans Iron / chemistry Molecular Structure Oxidation-Reduction / drug effects Pyridines / chemistry Ribonucleotide Reductases / antagonists & inhibitors Thiosemicarbazones / chemistry Tyrosine / chemistry
Anticancer drug Electrochemistry Ligand binding Redox chemistry Thiosemicarbazone metal complexes

Journal

Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry
ISSN: 1432-1327
Titre abrégé: J Biol Inorg Chem
Pays: Germany
ID NLM: 9616326

Informations de publication

Date de publication:
08 2019
Historique:
received: 18 04 2019
accepted: 03 06 2019
pubmed: 30 6 2019
medline: 14 7 2020
entrez: 29 6 2019
Statut: ppublish

Résumé

Triapine (3-AP), is an iron-binding ligand and anticancer drug that is an inhibitor of human ribonucleotide reductase (RNR). Inhibition of RNR by 3-AP results in the depletion of dNTP precursors of DNA, thereby selectively starving fast-replicating cancer cells of nucleotides for survival. The redox-active form of 3-AP directly responsible for inhibition of RNR is the Fe(II)(3-AP)

Identifiants

DOI: 10.1007/s00775-019-01675-0 PMID: 31250199 PMC: PMC7849610
pubmed: 31250199
doi: 10.1007/s00775-019-01675-0
pii: 10.1007/s00775-019-01675-0
pmc: PMC7849610
mid: NIHMS1663341
doi:

Substances chimiques

Antineoplastic Agents 0
Coordination Complexes 0
Enzyme Inhibitors 0
Pyridines 0
Thiosemicarbazones 0
3-aminopyridine-2-carboxaldehyde thiosemicarbazone 143621-35-6
Tyrosine 42HK56048U
Iron E1UOL152H7
Ribonucleotide Reductases EC 1.17.4.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

621-632

Subventions

Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States

Références

Graf N, Lippard SJ (2012) Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev 64:993–1004. https://doi.org/10.1016/j.addr.2012.01.007
doi: 10.1016/j.addr.2012.01.007 pubmed: 22289471 pmcid: 3342443
Reisner E, Arion VB, Keppler BK, Pombeiro AJL (2008) Electron-transfer activated metal-based anticancer drugs. Inorg Chim Acta 361:1569–1583. https://doi.org/10.1016/j.ica.2006.12.005
doi: 10.1016/j.ica.2006.12.005
Bruijnincx PC, Sadler PJ (2008) New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 12:197–206. https://doi.org/10.1016/j.cbpa.2007.11.013
doi: 10.1016/j.cbpa.2007.11.013 pubmed: 18155674 pmcid: 2923029
Alderden RA, Hall MD, Hambley TW (2009) The discovery and development of cisplatin. J Chem Educ 83:728. https://doi.org/10.1021/ed083p728
doi: 10.1021/ed083p728
Clarke MJ (2002) Ruthenium metallopharmaceuticals. Coord Chem Rev 232:69–93. https://doi.org/10.1016/S0010-8545(02)00025-5
doi: 10.1016/S0010-8545(02)00025-5
Galanski M, Arion V, Jakupec M, Keppler B (2003) Recent developments in the field of tumor-inhibiting metal complexes. Curr Pharm Des 9:2078–2089. https://doi.org/10.2174/1381612033454180
doi: 10.2174/1381612033454180 pubmed: 14529417
Liu M-C, Lin T-S, Cory JG et al (1996) Synthesis and biological activity of 3- and 5-amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J Med Chem 39:2586–2593. https://doi.org/10.1021/jm9600454
doi: 10.1021/jm9600454 pubmed: 8691457
Cory JG, Cory AH, Rappa G et al (1995) Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo. Adv Enzyme Regul 35:55–68. https://doi.org/10.1016/0065-2571(94)00005-N
doi: 10.1016/0065-2571(94)00005-N pubmed: 7572354
Finch RA, Liu M-C, Cory AH et al (1999) Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 39:3–12. https://doi.org/10.1016/S0065-2571(98)00017-X
doi: 10.1016/S0065-2571(98)00017-X pubmed: 10470363
Dai L, Lin Z, Qiao J et al (2017) Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. Oncogene 36:5068–5074. https://doi.org/10.1038/onc.2017.122
doi: 10.1038/onc.2017.122 pubmed: 28459467 pmcid: 5578886
Cory JG, Cory AH, Rappa G et al (1994) Inhibitors of ribonucleotide reductase. Biochem Pharmacol 48:335–344. https://doi.org/10.1016/0006-2952(94)90105-8
doi: 10.1016/0006-2952(94)90105-8 pubmed: 8053929
Finch RA, Liu MC, Grill SP et al (2000) Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59:983–991. https://doi.org/10.1016/S0006-2952(99)00419-0
doi: 10.1016/S0006-2952(99)00419-0 pubmed: 10692563
Nutting CM, Van Herpen CML, Miah AB et al (2009) Phase II study of 3-AP triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann Oncol 20:1275–1279. https://doi.org/10.1093/annonc/mdn775
doi: 10.1093/annonc/mdn775 pubmed: 19246715
Traynor AM, Lee J-W, Bayer GK et al (2010) A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs 28:91–97. https://doi.org/10.1007/s10637-009-9230-z
doi: 10.1007/s10637-009-9230-z pubmed: 19238328
Le TM, Poddar S, Capri JR et al (2017) ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nat Commun. https://doi.org/10.1038/s41467-017-00221-3
doi: 10.1038/s41467-017-00221-3 pubmed: 29162803 pmcid: 5698482
Aye Y, Long MJC, Stubbe J (2012) Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species. J Biol Chem 287:35768–35778. https://doi.org/10.1074/jbc.M112.396911
doi: 10.1074/jbc.M112.396911 pubmed: 22915594 pmcid: 3471726
Mathews CK (2016) The most interesting enzyme in the world. Structure 24:843–844. https://doi.org/10.1016/j.str.2016.05.006
doi: 10.1016/j.str.2016.05.006 pubmed: 27276424
Uhlin U, Eklund H (1994) Structure of ribonucleotide reductase protein R1. Nature 370:533–539. https://doi.org/10.1038/370533a0
doi: 10.1038/370533a0 pubmed: 8052308
Nordlund P, Reichard P (2006) Ribonucleotide reductases. Annu Rev Biochem 75:681–706. https://doi.org/10.1146/annurev.biochem.75.103004.142443
doi: 10.1146/annurev.biochem.75.103004.142443 pubmed: 16756507
Aird KM, Zhang R (2015) Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Lett 356:204–210
doi: 10.1016/j.canlet.2014.01.017 pubmed: 24486217
Richardson DR, Kalinowski DS, Richardson V et al (2009) 2-acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J Med Chem 52:1459–1470. https://doi.org/10.1021/jm801585u
doi: 10.1021/jm801585u pubmed: 19216562
Enyedy ÉA, Nagy NV, Zsigó É et al (2010) Comparative solution equilibrium study of the interactions of copper(II), iron(II) and zinc(II) with triapine (3-aminopyridine-2-carbaldehyde thiosemicarbazone) and related ligands. Eur J Inorg Chem 2010:1717–1728. https://doi.org/10.1002/ejic.200901174
doi: 10.1002/ejic.200901174
Enyedy É, Primik MF, Kowol CR et al (2011) Interaction of triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study. Dalton Trans 40:5895–5905. https://doi.org/10.1039/c0dt01835j
doi: 10.1039/c0dt01835j pubmed: 21523301 pmcid: 3372890
Kowol CR, Trondl R, Heffeter P et al (2009) Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) and novel insights into terminal dimethylation. J Med Chem 52:5032–5043. https://doi.org/10.1021/jm900528d
doi: 10.1021/jm900528d pubmed: 19637923
Pelosi G (2010) Thiosemicarbazone metal complexes: from structure to activity. Open Crystallogr J 3:16–28. https://doi.org/10.2174/1874846501003020016
doi: 10.2174/1874846501003020016
Antholine WE, Knight JM, Petering DH (1976) Inhibition of tumor cell transplantability by iron and copper complexes of 5-substituted 2-formylpyridine thiosemicarbazones. J Med Chem 19:339–341. https://doi.org/10.1021/jm00224a030
doi: 10.1021/jm00224a030 pubmed: 1249818
Wallace R, Richard Thomson J, Bell MJ, Skipper HE (1956) Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res 16:167–170
Agrawal KC, Sartorelli AC (1969) Potential antitumor agents. II. Effects of modifications in the side chain of 1-formylisoquinoline thiosemicarbazone. J Med Chem 12:771–774. https://doi.org/10.1021/jm00305a011
doi: 10.1021/jm00305a011 pubmed: 5812185
French FA, Blanz EJ (1965) The carcinostatic activity of α-N heterocyclic carboxaldehyde thiosemicarbazones. Cancer Res 25:1454–1458
pubmed: 5862990
Popović-Bijelić A, Kowol CR, Lind MES et al (2011) Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study. J Inorg Biochem 105:1422–1431. https://doi.org/10.1016/j.jinorgbio.2011.07.003
doi: 10.1016/j.jinorgbio.2011.07.003 pubmed: 21955844 pmcid: 3374975
Mooney PD, Booth BA, Moore EC et al (1974) Potential antitumor agents. Synthesis and biochemical properties of 5-N-alkylamino-, N,N-dialkylamino-, and N-alkylacetamido-1-formylisoquinoline thiosemicarbazones. J Med Chem 17:1145–1150. https://doi.org/10.1021/jm00257a004
doi: 10.1021/jm00257a004 pubmed: 4370274
Lin ZP, Belcourt MF, Carbone R et al (2007) Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress. Biochem Pharmacol 73:760–772. https://doi.org/10.1016/j.bcp.2006.11.014
doi: 10.1016/j.bcp.2006.11.014 pubmed: 17188250
Buss Joan L, Greene Bryan T, Turner JoLyn et al (2005) Iron chelators in cancer chemotherapy. Curr Top Med Chem 4:1623–1635. https://doi.org/10.2174/1568026043387269
doi: 10.2174/1568026043387269
Yu Y, Wong J, Lovejoy DB et al (2006) Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clin Cancer Res 12:6876–6883. https://doi.org/10.1158/1078-0432.CCR-06-1954
doi: 10.1158/1078-0432.CCR-06-1954 pubmed: 17145804
Kappus H (1986) Overview of enzyme systems involved in bioreduction of drugs and in redox cycling. Biochem Pharmacol 35:1–6. https://doi.org/10.1016/0006-2952(86)90544-7
doi: 10.1016/0006-2952(86)90544-7 pubmed: 2416318
Popović-Bijelić A, Kowol CR, Lind MES et al (2011) Ribonucleotide reductase inhibition by metal complexes of triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study. J Inorg Biochem 105:1422–1431. https://doi.org/10.1016/j.jinorgbio.2011.07.003
doi: 10.1016/j.jinorgbio.2011.07.003 pubmed: 21955844 pmcid: 3374975
Bernhardt PV, Sharpe PC, Islam M et al (2009) Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem 52:407–415. https://doi.org/10.1021/jm801012z
doi: 10.1021/jm801012z pubmed: 19090766
Kolesar JM, Schelman WR, Geiger PG et al (2008) Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. J Inorg Biochem 102:693–698. https://doi.org/10.1016/j.jinorgbio.2007.10.013
doi: 10.1016/j.jinorgbio.2007.10.013 pubmed: 18061679
Pelivan K, Miklos W, Van Schoonhoven S et al (2016) Differences in protein binding and excretion of triapine and its Fe(III) complex. J Inorg Biochem 160:61–69. https://doi.org/10.1016/j.jinorgbio.2015.10.006
doi: 10.1016/j.jinorgbio.2015.10.006 pubmed: 26507768

Auteurs

Sheba Plamthottam (S)

Department of Chemistry, University of California, Los Angeles, CA, 90095, USA.
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.

Daniel Sun (D)

Department of Chemistry, University of California, Los Angeles, CA, 90095, USA.
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.

Juno Van Valkenburgh (J)

Department of Chemistry, University of California, Los Angeles, CA, 90095, USA.
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.

Jeffrey Valenzuela (J)

Department of Chemistry, University of California, Los Angeles, CA, 90095, USA.

Bastian Ruehle (B)

Department of Chemistry, University of California, Los Angeles, CA, 90095, USA.

Dalton Steele (D)

Department of Chemistry, University of California, Los Angeles, CA, 90095, USA.
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.

Soumya Poddar (S)

Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.

Maxim Marshalik (M)

Department of Chemistry, University of California, Los Angeles, CA, 90095, USA.

Selena Hernandez (S)

Department of Chemistry, University of California, Los Angeles, CA, 90095, USA.

Caius Gabriel Radu (CG)

Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.

Jeffrey I Zink (JI)

Department of Chemistry, University of California, Los Angeles, CA, 90095, USA. zink@chem.ucla.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Activity and electrochemical properties: iron...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Activity and electrochemical properties: iron...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Activity and electrochemical properties: iron...
questionsmedicales.fr › Composés chimiques organiques › Complexes de coordination › Activity and electrochemical properties: iron...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Chimie physique › Électrochimie › Activity and electrochemical properties: iron...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Activity and electrochemical properties: iron...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Activity and electrochemical properties: iron...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Fer › Activity and electrochemical properties: iron...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Activity and electrochemical properties: iron...
questionsmedicales.fr › Métabolisme › Métabolisme énergétique › Oxydoréduction › Activity and electrochemical properties: iron...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Activity and electrochemical properties: iron...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Ribonucleotide reductases › Activity and electrochemical properties: iron...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Thiosemicarbazones › Activity and electrochemical properties: iron...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés cycliques › Acides aminés aromatiques › Tyrosine › Activity and electrochemical properties: iron...